Stay updated on Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.

Latest updates to the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden message in the study-record area, and the footer revision changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a standard error view and leaving the site chrome intact.SummaryDifference19%

- Check47 days agoChange DetectedThe page adds a 2018 NIH grant/contract funding note and updates the page revision to v3.6.6, removing the previous v3.6.5 reference.SummaryDifference0.0%

- Check61 days agoChange DetectedThe Plain Language Summary section was removed from the Study Details page, eliminating the patient-friendly overview of the KEYLYNK-010 study and its aims. The page now relies on more technical sections to describe the trial.SummaryDifference0.0%

- Check68 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, signaling a platform update to the page. No trial data or content changes are indicated by this text.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page now displays Revision: v3.6.4, replacing Revision: v3.6.3, indicating a small update to the page's content and metadata.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.